agencies to monitor the implementation of Presidential Executive Orders.

D. Division of Policy and Planning proposes and implements national policy on the CSE program and provides policy guidance and interpretations to states in developing and operating their programs according to federal law. It develops legislative proposals and regulations to implement new legislation, court decisions or directives from higher authority. The Division develops procedures for review and approval of state plans by the OCSE regional offices. It develops and monitors research, interstate, and other demonstration and evaluation studies and publishes program statistics. The Division is also responsible for strategic planning and performance measurements and standards development. It prepares legislative cost estimates and is responsible for national child support budget formulation.

E. Division of Consumer Services provides direction and leadership for a variety of consumer affairs activities in support of the nationwide child support enforcement program. Provides advice on strategies and approaches to be used to improve public understanding of and access to OCSE programs and policies. Develops and publishes informational materials. Promotes ''best'' child support practices to the public through monthly publication of the *Child Support Report.* Advises the Director and Deputy Director, OCSE of the impact of child support enforcement policy and program upon consumers and provides a focal point for intergovernmental and consumer relations and consultation. The Division is also responsible for operation of the OCSE Homepage on the internet and insuring that the information is placed thereon in a timely manner.

F. Division of State and Local Assistance, in concert with regional offices, provides information and assistance on Child Support Enforcement state operations. It provides national direction and leadership for training and technical assistance activities to increase Child Support Enforcement (CSE) program effectiveness both at Federal and State levels; develops guides and resource materials and serves as a clearinghouse for specialized program techniques for use by ACF regional offices and States; and ensures transfer of best practices among State and local CSE enforcement agencies. The Division, in consultation with the Division of Consumer Services, develops informational materials and operates a national CSE training center; provides logistical support for both training events and meetings; and monitors contracts with organizations affiliated with child support enforcement programs in the areas of training and technical assistance. The Division provides outreach and liaison services to a variety of special interest populations concerning establishment of paternity and collection of child support.

Dated: March 18, 1997.

Olivia A. Golden,

Principal Deputy Assistant Secretary for Children and Families.

[FR Doc. 97–7521 Filed 3–24–97; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

[Docket No. 91G–0495]

Cerestar USA, Inc., and Roquette America, Inc.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP 1G0376) proposing that β-cyclodextrin be affirmed as generally recognized as safe (GRAS) for use as a formulation aid in the production of dry flavoring mixes for preparation of cocktail-type alcoholic beverages.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3071.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of February 3, 1992 (57 FR 4043), FDA announced that a petition (GRASP 1G0376) had been filed by the law offices of Keller and Heckman, 1001 G St. NW., suite 500 West, Washington, DC 20001, on behalf of Cerestar USA, Inc. (formerly, American Maize-Products Co.), 1100 Indianapolis Blvd., Hammond, IN 46320–1094, and Roquette America, Inc. (formerly, Roquette Corp.), 1550 Northwestern Ave., Gurnee, IL 60031–2392. The petition proposed that β-cyclodextrin be affirmed as GRAS for use as a formulation aid in the production of dry flavoring mixes for the preparation of cocktail-type alcoholic beverages.

Recently, the petitioners submitted another petition (GRASP 6G0421) that requests GRAS affirmation of β-cyclodextrin for use as a flavor protectant in human food. The filing of this petition was announced in a notice that published in the **Federal Register** of September 20, 1996 (61 FR 49472). The general use in food that is proposed in petition GRASP 6G0421 encompasses the limited use presently proposed in GRASP 1G0376. Accordingly, the petitioners have requested the withdrawal of GRASP 1G0376. Cerestar USA, Inc., and Roquette America, Inc., have now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: February 27, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–7479 Filed 3–24–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 97M–0084]

VISX, Inc.; Premarket Approval of VISX Excimer Laser System (Models B and C) for Photorefractive Keratectomy (PRK)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by VISX, Inc., Santa Clara, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the VISX Excimer Laser System (Models B and C) for PRK. After reviewing the recommendation of the Ophthalmic Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of March 27, 1996, of the approval of the application.

DATES: Petitions for administrative review by April 24, 1997.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Jan C. Callaway, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2018.

SUPPLEMENTARY INFORMATION: On June 15, 1996, VISX, Inc., Santa Clara, CA 95051, submitted to CDRH an application for premarket approval of the VISX Excimer Laser System (Models B and C). The device is an argon

fluoride excimer laser and is indicated for PRK treatments: (1) For the reduction or elimination of mild to moderate myopia (nearsightedness) of between -1.0 to -6.0 diopters spherical equivalent at the corneal plane, in patients with less than or equal to 1.0 diopters of astigmatism; (2) in patients with documented evidence of a change in manifest refraction of less than or equal to 0.50 diopters (in both cylinder and sphere components) per year for at least 1 year prior to the date of preoperative examination; and (3) in patients who are 18 years of age or older.

On October 20, 1995, the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended conditional approval of the application. On March 27, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under 21 CFR part 12 of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under 21 CFR 10.33(b). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before April 24, 1997, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: February 20, 1997.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 97–7478 Filed 3–24–97; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

[Document Identifier: HCFA–R–183]

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Extension of currently approved collection; *Title of Information Collection:* Voluntary Customer Surveys to Implement Executive Order 12862 within HCFA; *Form No.:* HCFA–R–183; *Use:* These voluntary customer surveys will be used to implement E.O. 12862 to ascertain customer satisfaction with HCFA programs in terms of service quality. Surveys will involve individuals that are in direct or indirect beneficiaries of HCFA service and/or assistance, not partners. *Frequency:* Annually; *Affected Public:* Individuals or households; *Number of Respondents:* 1; *Total Annual Responses:* 1; *Total Annual Hours:* 1.

To obtain copies of the supporting statement for the proposed paperwork collections referenced above, access HCFA's WEB SITE ADDRESS at http://www.hcfa.gov/regs/prdact95.htm, or to obtain the supporting statement and any related forms, E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Analysis and Planning Staff, Attention: John Burke, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: March 18, 1997.

Edwin J. Glatzel,

Director, Management Analysis and Planning Staff, Office of Financial and Human Resources.

[FR Doc. 97–7402 Filed 3–24–97; 8:45 am]

BILLING CODE 4120–03–P

Agency Information Collection Activities: Proposed Collection: Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposals for the collection of information. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.